- Home
- BCDA vs KPRX Comparison
BCDA vs KPRX Comparison
Compare BCDA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- KPRX
- Stock Information
- Founded
- BCDA N/A
- KPRX 1998
- Country
- BCDA United States
- KPRX United States
- Employees
- BCDA N/A
- KPRX N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BCDA Health Care
- KPRX Health Care
- Exchange
- BCDA Nasdaq
- KPRX Nasdaq
- Market Cap
- BCDA 11.3M
- KPRX 9.2M
- IPO Year
- BCDA N/A
- KPRX N/A
- Fundamental
- Price
- BCDA $1.39
- KPRX $2.50
- Analyst Decision
- BCDA Strong Buy
- KPRX Strong Buy
- Analyst Count
- BCDA 1
- KPRX 1
- Target Price
- BCDA $25.00
- KPRX $10.00
- AVG Volume (30 Days)
- BCDA 306.5K
- KPRX 52.9K
- Earning Date
- BCDA 11-12-2025
- KPRX 11-07-2025
- Dividend Yield
- BCDA N/A
- KPRX N/A
- EPS Growth
- BCDA N/A
- KPRX N/A
- EPS
- BCDA N/A
- KPRX N/A
- Revenue
- BCDA N/A
- KPRX N/A
- Revenue This Year
- BCDA N/A
- KPRX N/A
- Revenue Next Year
- BCDA N/A
- KPRX N/A
- P/E Ratio
- BCDA N/A
- KPRX N/A
- Revenue Growth
- BCDA N/A
- KPRX N/A
- 52 Week Low
- BCDA $1.00
- KPRX $2.21
- 52 Week High
- BCDA $3.20
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- BCDA 42.69
- KPRX 41.27
- Support Level
- BCDA $1.40
- KPRX $2.21
- Resistance Level
- BCDA $1.52
- KPRX $2.80
- Average True Range (ATR)
- BCDA 0.11
- KPRX 0.15
- MACD
- BCDA 0.02
- KPRX -0.03
- Stochastic Oscillator
- BCDA 32.82
- KPRX 39.54
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.